FDA Drug recall D-0348-2023
Warfarin Sodium Tablets, USP 1 mg, 100-count bottle, Rx Only, Distributed by: Rising Health, LLC, Saddle Brook, NJ 07663, NDC# 57237-119-01
- FDA Drug
- Class II
- terminated
- Published 2023-03-01
On 2023-03-01 the FDA classified a Class II recall of Warfarin Sodium Tablets, USP 1 mg, 100-count bottle, Rx Only, Distributed by: Rising Health, LLC, Saddle Brook, NJ 07663, NDC# 57237-119-01 by Rising Pharmaceuticals, citing failed Impurities/Degradation Specifications.
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-0348-2023 |
| Classification | Class II |
| Status | terminated |
| Initiated | 2023-02-15 |
| Published | 2023-03-01 |
| Last updated | 2026-09-13 11:52 UTC |
| Company | Rising Pharmaceuticals |
| Distribution | US |
Product
Warfarin Sodium Tablets, USP 1 mg, 100-count bottle, Rx Only, Distributed by: Rising Health, LLC, Saddle Brook, NJ 07663, NDC# 57237-119-01
Reason
Failed Impurities/Degradation Specifications
Identifiers
| code_info | Batch #: NB101596, Exp. 04/30/2023 |
|---|
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0348-2023%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.